Serotonergic Receptor 5-HT2A in the Cardiosympathovagal System

Kermorgant, Marc; Traon, Anne Pavy‐Le; Senard, J. M.; Arvanitis, Dina N.

doi:10.1007/978-3-319-70474-6_6

Cited by 4 publications

(4 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further, we found that shaking behavior is preceded by hemodynamic BvSO activity, which (in addition to the factors discussed above) may be driven by pre-event arousal of the heart, local diameter changes in brain-surface arteries [46], and/or the meeting of cortical energy demands. Despite the well-known role of 5-HT2A receptors in cardiovascular functioning [26,47], only limited research has been devoted to a possible disentanglement of vascular and neuronal constituents of psychedelic drug action [48,49]. A future combination of voltage imaging with techniques such as pulse oximetry [35], functional near-infrared spectroscopy [50], and/or laser speckle contrast imaging [51] might help and tell both constituents apart.…”

Section: Discussionmentioning

confidence: 99%

Cortical Correlates of Psychedelic-Induced Shaking Behavior Revealed by Voltage Imaging

Buchborn

Lyons

Song

et al. 2023

IJMS

View full text Add to dashboard Cite

(1) From mouse to man, shaking behavior (head twitches and/or wet dog shakes) is a reliable readout of psychedelic drug action. Shaking behavior like psychedelia is thought to be mediated by serotonin 2A receptors on cortical pyramidal cells. The involvement of pyramidal cells in psychedelic-induced shaking behavior remains hypothetical, though, as experimental in vivo evidence is limited. (2) Here, we use cell type-specific voltage imaging in awake mice to address this issue. We intersectionally express the genetically encoded voltage indicator VSFP Butterfly 1.2 in layer 2/3 pyramidal neurons. We simultaneously capture cortical hemodynamics and cell type-specific voltage activity while mice display psychedelic shaking behavior. (3) Shaking behavior is preceded by high-frequency oscillations and overlaps with low-frequency oscillations in the motor cortex. Oscillations spectrally mirror the rhythmics of shaking behavior and reflect layer 2/3 pyramidal cell activity complemented by hemodynamics. (4) Our results reveal a clear cortical fingerprint of serotonin-2A-receptor-mediated shaking behavior and open a promising methodological avenue relating a cross-mammalian psychedelic effect to cell-type specific brain dynamics.

show abstract

Section: Discussionmentioning

confidence: 99%

Cortical Correlates of Psychedelic-Induced Shaking Behavior Revealed by Voltage Imaging

Buchborn

Lyons

Song

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Serotonin is central to the development and function of two key stress response systems—the locus-coeruleus-norepinephrine (autonomic nervous system [ANS]) and the hypothalamic-pituitary-adrenal (HPA) systems [ 28 - 30 ], which may illustrate sites affected by prenatal exposure to serotonin reuptake inhibitors on stress responses [ 31 - 33 ]. The relationship between 5-HT and stress reactivity is bidirectional; stressors appear to alter 5-HT metabolism as well as bias how one copes with subsequent stressful challenges [ 32 , 34 ].…”

Section: Introductionmentioning

confidence: 99%

Associations Between Prenatal Exposure to Serotonergic Medications and Biobehavioral Stress Regulation: Protocol for a Systematic Review and Meta-analysis

Zusman¹,

Lavu²,

Pawliuk³

et al. 2022

JMIR Res Protoc

View full text Add to dashboard Cite

Background Up to 20% of mothers experience antenatal depression and approximately 30% of these women are treated with serotonergic psychotropic pharmacological therapy during pregnancy. Serotonergic antidepressants readily cross the placenta and the fetal blood-brain barrier, altering central synaptic serotonin signaling and potentially altering serotonin levels in the developing fetal brain. Objective The aim of this study is to assess the impact of prenatal exposure to serotonergic antidepressants, accounting for maternal mood disturbances, on markers of stress regulation during childhood. Methods We will follow PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and will search MEDLINE, Embase, CINAHL, PsycINFO, and ClinicalTrials.gov for full-length studies that assessed physiological (eg, cortisol level, heart rate variability, salivary amylase, pupillary size, C-reactive protein) indices of stress regulation in children of pregnant people who were treated with a serotonergic antidepressant at any point during pregnancy. We will assess the quality of observational studies using the Newcastle-Ottawa Scale and the quality of experimental studies using the Cochrane risk-of-bias tool. When possible, we will conduct a random-effects meta-analysis. If meta-analysis is not possible, we will conduct a narrative review. If a sufficient number of studies are found, we will perform subgroup analysis and assess outcomes measured by drug class, dose, trimester of exposure, and child’s age and gender. Results We registered our review protocol with PROSPERO (International Prospective Register of Systematic Reviews; CRD42021275750), completed the literature search, and initiated title and abstract review in August 2021. We expect to finalize this review by April 2022. Conclusions Findings should identify the impact of prenatal antidepressant effects on stress regulation and distinguish it from the impact of prenatal exposure to maternal mood disturbances. This review should inform decisions about serotonergic antidepressant use during pregnancy. Trial Registration PROSPERO CRD42021275750; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=275750 International Registered Report Identifier (IRRID) PRR1-10.2196/33363

show abstract

“…Serotonin is central to the development and function of two key stress response systems-the locus-coeruleus-norepinephrine (autonomic nervous system [ANS]) and the hypothalamic-pituitary-adrenal (HPA) systems [28][29][30], which may illustrate sites affected by prenatal exposure to serotonin reuptake inhibitors on stress responses [31][32][33]. The relationship between 5-HT and stress reactivity is bidirectional; stressors appear to alter 5-HT metabolism as well as bias how one copes with subsequent stressful challenges [32,34].…”

Section: Introductionmentioning

confidence: 99%

Associations Between Prenatal Exposure to Serotonergic Medications and Biobehavioral Stress Regulation: Protocol for a Systematic Review and Meta-analysis (Preprint)

Zusman¹,

Lavu²,

Pawliuk³

et al. 2021

Preprint

View full text Add to dashboard Cite

BACKGROUND Up to 20% of mothers experience antenatal depression and approximately 30% of these women are treated with serotonergic psychotropic pharmacological therapy during pregnancy. Serotonergic antidepressants readily cross the placenta and the fetal blood-brain barrier, altering central synaptic serotonin signaling and potentially altering serotonin levels in the developing fetal brain. OBJECTIVE The aim of this study is to assess the impact of prenatal exposure to serotonergic antidepressants, accounting for maternal mood disturbances, on markers of stress regulation during childhood. METHODS We will follow PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and will search MEDLINE, Embase, CINAHL, PsycINFO, and ClinicalTrials.gov for full-length studies that assessed physiological (eg, cortisol level, heart rate variability, salivary amylase, pupillary size, C-reactive protein) indices of stress regulation in children of pregnant people who were treated with a serotonergic antidepressant at any point during pregnancy. We will assess the quality of observational studies using the Newcastle-Ottawa Scale and the quality of experimental studies using the Cochrane risk-of-bias tool. When possible, we will conduct a random-effects meta-analysis. If meta-analysis is not possible, we will conduct a narrative review. If a sufficient number of studies are found, we will perform subgroup analysis and assess outcomes measured by drug class, dose, trimester of exposure, and child’s age and gender. RESULTS We registered our review protocol with PROSPERO (International Prospective Register of Systematic Reviews; CRD42021275750), completed the literature search, and initiated title and abstract review in August 2021. We expect to finalize this review by April 2022. CONCLUSIONS Findings should identify the impact of prenatal antidepressant effects on stress regulation and distinguish it from the impact of prenatal exposure to maternal mood disturbances. This review should inform decisions about serotonergic antidepressant use during pregnancy. CLINICALTRIAL PROSPERO CRD42021275750; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=275750 INTERNATIONAL REGISTERED REPORT PRR1-10.2196/33363

show abstract

Serotonergic Receptor 5-HT2A in the Cardiosympathovagal System

Cited by 4 publications

References 50 publications

Cortical Correlates of Psychedelic-Induced Shaking Behavior Revealed by Voltage Imaging

Cortical Correlates of Psychedelic-Induced Shaking Behavior Revealed by Voltage Imaging

Associations Between Prenatal Exposure to Serotonergic Medications and Biobehavioral Stress Regulation: Protocol for a Systematic Review and Meta-analysis

Associations Between Prenatal Exposure to Serotonergic Medications and Biobehavioral Stress Regulation: Protocol for a Systematic Review and Meta-analysis (Preprint)

Contact Info

Product

Resources

About